Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

July 31, 2012

Conditions

Stage III MelanomaStage IV Melanoma

Interventions

BIOLOGICAL

MKC1106-MT

Cancer Vaccine, Immunotherapy, Melanoma

Trial Locations (4)

Martin Memorial, Stuart

Nevada Cancer Institute, Las Vegas

The Angeles Clinic and Research Institute, Los Angeles

UCLA Medical Center, Los Angeles